drugset / Trial / NCT00891384

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

NCT00891384

RandomizedParallel-groupSingle-blindTreatment

Summary

This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation as first line therapy.

Timeline

Start
2009-04-01
Primary completion
2017-06-22
Completion
2017-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 5 mg
Subject Lenalidomide Other / unclassified 25 mg

Indications